39:{"drug_id":928422,"title":"Pregabalin","ind":"FDA-Labeled Indications

Diabetic peripheral neuropathy - Neuropathic pain
Fibromyalgia
Neuropathic pain - Spinal cord injury
Partial seizure; Adjunct
Postherpetic neuralgia

Non-FDA Labeled Indications

Generalized anxiety disorder
Restless legs syndrome

","adult":"$3a","ped":"General Dosage Information

safety and efficacy have not been established in pediatric patients

","side":"Common

Cardiovascular:Peripheral edema (5% to 12%)
Endocrine metabolic:Increased appetite (5%), Weight gain (3.3% to 12%)
Gastrointestinal:Constipation (4% to 8.2%), Xerostomia (2.3% to 11%)
Neurologic:Asthenia (5% to 10%), Ataxia (3% to 15%), Dizziness (9.1% to 42.7%), Headache (5.6% to 9.3%), Incoordination (2% to 10.1%), Somnolence (10.2% to 35.7%), Tremor (1% to 11.2%)
Ophthalmic:Blurred vision (3.4% to 10.1%), Diplopia (2% to 9%)
Psychiatric:Disturbance in thinking (2% to 8%), Euphoria (2% to 6%)
Respiratory:Nasopharyngitis (8.2%)
Other:Fatigue (7% to 11%)

Serious

Hepatic:Jaundice
Immunologic:Hypersensitivity reaction
Musculoskeletal:Increased creatine kinase level (1.5% to 2.7%)
Psychiatric:Suicidal thoughts
Other:Angioedema

","prgnancy":"

C (FDA)
B3 (AUS)

","intermajer":"

Orlistat (probable)","clinical":"

Patient should avoid activities requiring mental alertness or coordination until drug effects are realized, as drug may cause dizziness, blurred vision, and somnolence.
Adverse effects to a fetus may be caused by either male or female patients receiving this drug. Emphasize the use of reliable contraception to patient.
Drug may cause constipation, dry mouth, ataxia, diplopia, weight gain, edema, and difficulty with concentration or attention.
Advise patient against sudden discontinuation of drug, as adverse effects are enhanced including increased seizure frequency.
Patient should avoid drinking alcohol or using CNS depressants during therapy, as these may potentiate sedative effects.

","admin":"Oral

may take with or without food

","interminor":null,"contra":null,"clas":"Gamma Aminobutyric Acid (class)","mode":"Pregabalin is a gamma-aminobutyric acid (GABA) analog that strongly binds to the alpha(2)-delta site (a subunit of voltage-gated calcium channels) in CNS tissues. The exact mechanism of action is not fully understood. Binding to the alpha(2)-delta subunit may be involved in pregabalin's effects on neuropathic pain and seizure control. Pregabalin reduces the calcium-dependent release of pro-nociceptive neurotransmitters, possibly by modulation of calcium channel function. Pregabalin may also interact with descending noradrenergic and serotonergic pathways in the brainstem that modulate pain transmission in the spinal cord.
"}

REGAPEN (Pregabalin - Capsule 150 mg) – Full Drug Info.

SCIENTIFIC NAME

INDICATIONS

CLASSIFICATION

MECHANISM OF ACTION

CLINICAL USE

ADULT DOSE

PEDIATRIC DOSE

ADMINISTRATION

CONTRAINDICATIONS

SIDE EFFECTS

PREGNANCY

MAJOR INTERACTIONS

MINOR INTERACTIONS